Phaseline

Companies › MedPacto

MedPacto: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vactosertib
TGF-beta receptor type I inhibitor
TGFBR1Phase 1Osteosarcoma; Adenocarcinoma EsophagusDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06044311VactosertibPhase 2Adenocarcinoma EsophagusOncologyMar 2027
NCT05588648VactosertibPhase 1OsteosarcomaOncologyDec 2027

Targets

TGFBR1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.